Document Detail

Preservation of regional and global left ventricular function by intracoronary infusion with oxygenated fluorocarbon emulsion Therox in dogs.
MedLine Citation:
PMID:  8461436     Owner:  NLM     Status:  MEDLINE    
We tested the oxygen transport and delivery capacity of the novel perfluorocarbon emulsion, Therox (F44E, 1,2-bis-perfluorobutyl-ethylene) by comparing left ventricular regional and global function in dogs during perfusion of the left anterior descending coronary artery (LAD) with oxygenated Krebs buffer and oxygenated Therox emulsion (20% w/v) at 20 ml/min for two separate 3 min periods. During LAD perfusion with oxygenated Krebs buffer, complete loss of systolic wall thickening in the LAD perfusion area was observed, dP/dt was significantly reduced and left ventricular end-diastolic pressure (LVEDP) was increased. In contrast, LAD perfusion with oxygenated Therox maintained regional wall thickening at 60-70% of control and completely preserved global function as measured by dP/dt and LVEDP. Thus, Therox is an effective oxygen carrier in this animal model.
M J Thoolen; D E Rasbach; J H Shaw; S Raynolds; P B Timmermans
Related Documents :
15745806 - Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin.
21690976 - Self-diffusion in sodium under pressure revisited.
12494886 - Ultrasound guided, pre-radiation oxygen measurements using polarographic oxygen needle ...
96706 - Nitroglycerin as a hypotensive drug during general anesthesia.
3664996 - Inconsistency of the slope and the volume intercept of the end-systolic pressure-volume...
20829496 - Onset of airflow limitation in a collapsible tube model: impact of surrounding pressure...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology     Volume:  21     ISSN:  1055-7172     ISO Abbreviation:  Biomater Artif Cells Immobilization Biotechnol     Publication Date:  1993  
Date Detail:
Created Date:  1993-05-04     Completed Date:  1993-05-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9111988     Medline TA:  Biomater Artif Cells Immobilization Biotechnol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  53-62     Citation Subset:  IM    
Du Pont Merck Pharmaceutical Company, Wilmington, DE 19898.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biocompatible Materials
Disease Models, Animal
Drug Evaluation, Preclinical
Fluorocarbons / administration & dosage,  pharmacology*
Myocardial Ischemia / prevention & control*
Oxygen / administration & dosage,  metabolism
Ventricular Function, Left / drug effects*
Reg. No./Substance:
0/Biocompatible Materials; 0/Buffers; 0/Fluorocarbons; 7782-44-7/Oxygen; 84551-43-9/bis(perfluorobutyl)ethene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Release of chemicals from polyurethane foam in the Même breast implant.
Next Document:  In vitro toxicity of biomaterials determined with cell density, total protein, cell cycle distributi...